Developer docs
API playgroundTry for free, no card

Search company profiles

Ultromics

Full company profile

uuid00004qn

Namestring
Ultromics
Legal namestring
Ultromics Limited
Websiteurl
ultromics.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Ultromics is a University of Oxford spin-out (founded 2017 by Dr. Ross Upton and Prof. Paul Leeson) that builds AI-powered software for analyzing routine echocardiograms to detect complex cardiovascular disease. The company's flagship platform, EchoGo, applies 3D convolutional neural networks trained on more than 10 years of outcome-annotated clinical data to deliver automated diagnostic reports within roughly 20 minutes via DICOM workflow integration with hospital PACS systems. The platform powers three FDA-cleared medical devices: EchoGo Heart Failure (the first and only FDA-cleared diagnostic support tool for HFpEF detection, with 90% sensitivity and 86% specificity), EchoGo Amyloidosis (the first FDA-cleared AI tool for cardiac amyloidosis detection, with Breakthrough Device Designation and 85% sensitivity / 93% specificity), and EchoGo Core (automated EF, GLS, and volume quantification with zero inter-observer variability). The company is based in Oxford, UK with a U.S. subsidiary in Atlanta and commercial leadership in Dallas.

Ultromics monetizes primarily through a per-analysis revenue model: EchoGo Heart Failure is reimbursable under Medicare CPT code 0932T at $316 per analysis in outpatient settings, with inpatient reimbursement following DRG methodology. The company supplements per-analysis revenue with enterprise licensing agreements with major health systems and operates a self-serve trial option and a Microsoft Azure Marketplace listing. To date, EchoGo has processed more than 430,000 clinical cases across hospitals in the U.S. and U.K., supported by 50+ peer-reviewed publications and clinical validation partnerships with Mayo Clinic, Cleveland Clinic, Northwestern Medicine, Beth Israel Deaconess, MedStar Health, NHS UK, and the Foundation for the National Institutes of Health. Go-to-market is enterprise field sales, complemented by pharma co-development partnerships with Johnson & Johnson Innovative Medicine and Pfizer on the EchoGo Amyloidosis program.

The company has raised approximately $110 million+ in venture funding across multiple rounds, including a $33 million Series B (2021, led by Blue Venture Fund with Optum Ventures and GV) and a $55 million Series C (July 2025, co-led by L&G, Allegis Capital, and Lightrock), plus a strategic investment from the American Heart Association's Go Red for Women Venture Fund in December 2025. Investors also include Oxford Science Enterprises, UCM Ventures, and Nina Capital. Customers are large academic medical centers and integrated delivery networks in the U.S. and U.K., and the company is actively scaling U.S. commercial operations following Medicare reimbursement and the 2024 FDA clearance of EchoGo Amyloidosis.

Short descriptiontext

Ultromics develops AI-powered echocardiography analysis software that detects complex cardiac diseases including HFpEF and cardiac amyloidosis, serving U.S. and U.K. hospitals and health systems with FDA-cleared, Medicare-reimbursable diagnostic tools integrated into PACS workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cardiac diagnostics, echocardiography analysis software, heart failure detection, medical imaging AI, cardiac amyloidosis screening
Industry3 codes
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI Cardiac Diagnostics Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1EchoGo Heart Failure Analysis
TypeSubscription Recurring
Description

Per-analysis Medicare reimbursement for AI cardiac diagnostics. CPT code 0932T provides $316 per analysis for outpatient settings, with DRG payment methodology for inpatient.

ultromics.com
2SaaS Platform Services
TypeUsage Based
Description

Cloud-based AI diagnostic platform that processes echocardiograms and delivers automated DICOM reports to PACS systems. Revenue generated per analysis and through enterprise licensing agreements with healthcare systems.

ultromics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1CPT code 0932T - EchoGo Heart Failure outpatient analysis
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

$316 per analysis (covered by Medicare and select commercial insurers)

ultromics.com
2Inpatient EchoGo analysis
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Reimbursed under DRG payment methodology

ultromics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1EchoGo Heart Failure
Description

FDA-cleared AI-powered diagnostic support tool for detecting heart failure with preserved ejection fraction (HFpEF) from routine echocardiogram analysis.

ultromics.com
+3 more records
Core offering1 text field

Ultromics develops and sells the EchoGo platform, a cloud-based AI-powered SaaS solution that analyzes routine echocardiogram video clips to detect complex cardiac diseases including heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. The platform powers FDA-cleared medical devices (EchoGo Heart Failure, EchoGo Amyloidosis, and EchoGo Core) that deliver automated structured DICOM reports to PACS systems within 20 minutes, targeting hospitals and healthcare systems in the U.S. and U.K.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • EchoGo Heart Failure achieves 90% sensitivity and 86% specificity for HFpEF detection
+5 more records
Product overview1 text field

Ultromics offers the EchoGo platform, a unified AI-powered SaaS solution for cardiovascular disease detection through echocardiography analysis. The platform comprises two FDA-cleared diagnostic modules: EchoGo Heart Failure for detecting heart failure with preserved ejection fraction (HFpEF), and EchoGo Amyloidosis for cardiac amyloidosis screening. Both modules leverage deep learning computer vision models trained on over 10 years of outcome data to analyze routine echocardiogram video clips and deliver automated diagnostic reports within 20 minutes. The platform integrates with existing hospital PACS infrastructure and is reimbursable under CPT code 0932T ($316 per analysis).

Product and service1 record
1EchoGo Platform
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Co-development partner for EchoGo Amyloidosis device, contributing to FDA Breakthrough Device Designation and marketing authorization through TAP program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration to develop EchoGo Amyloidosis AI platform using artificial intelligence to detect cardiac amyloidosis from routine echocardiograms. Platform received FDA Breakthrough Device Status and is prepared for U.S. commercialization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key clinical validation partner; built EchoGo in collaboration with Mayo Clinic; hosts key opinion leaders including Dr. Patricia Pellikka; contributed to multiple clinical studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology built in partnership with NHS for echocardiography analysis; supported by NHS England; deployed across NHS sites.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in Accelerating Medicines Partnership Heart Failure (AMP HF) 5-year, $37 million multi-stakeholder collaboration to investigate HFpEF.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ASE IRT partnership; member and leader of ASE AI taskforce setting principles and guidance for AI in echocardiography.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spin-out company founded at Oxford University in 2017; ongoing research partnership with Oxford Cardiovascular Clinical Research Facility.

Strategic tierCoreTypeTechnology or Integration
Description

Clinical validation partner; conducted utility study of EchoGo for COVID-19 risk stratification.

Strategic tierCoreTypeTechnology or Integration
Description

WASE-COVID study partner; Director Dr. Federico Asch served as principal investigator.

Strategic tierCoreTypeTechnology or Integration
Description

EchoGo HFpEF clinical deployment partner; published initial experience study with Dr. Akhil Narang.

11Microsoft Azure
Strategic tierCoreTypeTechnology or Integration
Description

Cloud infrastructure provider for EchoGo platform; data centers in UK and North America.

ultromics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cleerly applies AI to cardiac CT imaging for plaque and ischemia assessment; competes with Ultromics in AI-driven cardiovascular diagnostics but uses a different imaging modality and use case.

2Caption Health (GE HealthCare)
TypeDirect peer
Description

Acquired by GE HealthCare in 2023, Caption Health was the leading AI-guided echocardiography acquisition and analysis platform and is the closest direct competitor to Ultromics' EchoGo platform, serving similar cardiology workflows.

TypeDirect peer
Description

Us2.ai develops AI software that automates echocardiogram analysis for cardiac function assessment, directly competing with EchoGo Core and EchoGo Heart Failure on AI-driven cardiac measurement and disease detection.

4DiA Imaging Analysis
TypeDirect peer
Description

DiA Imaging Analysis provides AI-based ultrasound image analysis tools, including cardiac applications, that compete with Ultromics' EchoGo Core automated measurement capabilities for echocardiography.

TypeEmerging player
Description

HeartFlow provides AI-driven cardiac CT FFR analysis for coronary disease; a comparable AI-cardiology-diagnostics peer but focused on CT rather than echocardiography and ischemia rather than HFpEF/amyloidosis.

TypeEmerging player
Description

Eko Health builds AI-enabled cardiac ultrasound and digital stethoscope devices with embedded AI for cardiac disease detection; competes at the intersection of point-of-care ultrasound and AI diagnostics adjacent to Ultromics' echo AI.

TypeEmerging player
Description

RapidAI offers AI imaging analysis platforms initially focused on stroke and expanding into other vascular/cardiac conditions; comparable as an AI imaging diagnostics vendor to hospital systems.

8Tempus Labs
TypeBroad incumbent
Description

Tempus is a large AI-driven precision medicine company with capabilities spanning imaging, pathology, and clinical data; while not a focused echocardiography peer, it competes broadly for AI diagnostics budget and hospital AI partnerships.

TypeEmerging player
Description

Viz.ai applies AI to medical imaging workflow across multiple specialties, including cardiology, and competes with Ultromics in AI-powered cardiac imaging analytics and hospital deployment.

TypeBroad incumbent
Description

Philips operates Intellispace Cardiovascular and cardiology informatics suites sold into the same hospital systems as Ultromics; multiple Ultromics executives came from Philips cardiology informatics, making it the most directly comparable incumbent competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ultromics

AI Cardiac Diagnostics Softwareultromics.com

Ultromics develops AI-powered echocardiography analysis software that detects complex cardiac diseases including HFpEF and cardiac amyloidosis, serving U.S. and U.K. hospitals and health systems with FDA-cleared, Medicare-reimbursable diagnostic tools integrated into PACS workflows.

What Ultromics does

Ultromics is a University of Oxford spin-out (founded 2017 by Dr. Ross Upton and Prof. Paul Leeson) that builds AI-powered software for analyzing routine echocardiograms to detect complex cardiovascular disease. The company's flagship platform, EchoGo, applies 3D convolutional neural networks trained on more than 10 years of outcome-annotated clinical data to deliver automated diagnostic reports within roughly 20 minutes via DICOM workflow integration with hospital PACS systems. The platform powers three FDA-cleared medical devices: EchoGo Heart Failure (the first and only FDA-cleared diagnostic support tool for HFpEF detection, with 90% sensitivity and 86% specificity), EchoGo Amyloidosis (the first FDA-cleared AI tool for cardiac amyloidosis detection, with Breakthrough Device Designation and 85% sensitivity / 93% specificity), and EchoGo Core (automated EF, GLS, and volume quantification with zero inter-observer variability). The company is based in Oxford, UK with a U.S. subsidiary in Atlanta and commercial leadership in Dallas.

Ultromics monetizes primarily through a per-analysis revenue model: EchoGo Heart Failure is reimbursable under Medicare CPT code 0932T at $316 per analysis in outpatient settings, with inpatient reimbursement following DRG methodology. The company supplements per-analysis revenue with enterprise licensing agreements with major health systems and operates a self-serve trial option and a Microsoft Azure Marketplace listing. To date, EchoGo has processed more than 430,000 clinical cases across hospitals in the U.S. and U.K., supported by 50+ peer-reviewed publications and clinical validation partnerships with Mayo Clinic, Cleveland Clinic, Northwestern Medicine, Beth Israel Deaconess, MedStar Health, NHS UK, and the Foundation for the National Institutes of Health. Go-to-market is enterprise field sales, complemented by pharma co-development partnerships with Johnson & Johnson Innovative Medicine and Pfizer on the EchoGo Amyloidosis program.

The company has raised approximately $110 million+ in venture funding across multiple rounds, including a $33 million Series B (2021, led by Blue Venture Fund with Optum Ventures and GV) and a $55 million Series C (July 2025, co-led by L&G, Allegis Capital, and Lightrock), plus a strategic investment from the American Heart Association's Go Red for Women Venture Fund in December 2025. Investors also include Oxford Science Enterprises, UCM Ventures, and Nina Capital. Customers are large academic medical centers and integrated delivery networks in the U.S. and U.K., and the company is actively scaling U.S. commercial operations following Medicare reimbursement and the 2024 FDA clearance of EchoGo Amyloidosis.

Ultromics firmographics

Firmographics
Name
Ultromics
Legal name
Ultromics Limited
Website
https://ultromics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Ultromics develops AI-powered echocardiography analysis software that detects complex cardiac diseases including HFpEF and cardiac amyloidosis, serving U.S. and U.K. hospitals and health systems with FDA-cleared, Medicare-reimbursable diagnostic tools integrated into PACS workflows.
Ownership category
akta.pro rank

Ultromics industry classification

Industry
Product category
AI Cardiac Diagnostics Software
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • AI cardiac diagnostics
  • Echocardiography analysis software
  • Heart failure detection
  • Medical imaging AI
  • Cardiac amyloidosis screening

Where Ultromics is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Ultromics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. EchoGo Heart Failure Analysis: Per-analysis Medicare reimbursement for AI cardiac diagnostics. CPT code 0932T provides $316 per analysis for outpatient settings, with DRG payment methodology for inpatient.
  2. SaaS Platform Services: Cloud-based AI diagnostic platform that processes echocardiograms and delivers automated DICOM reports to PACS systems. Revenue generated per analysis and through enterprise licensing agreements with healthcare systems.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goCPT code 0932T - EchoGo Heart Failure outpatient analysis
Transaction based/ take ratePay-as-you-goInpatient EchoGo analysis

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Ultromics product offering

Product offering

Core offering

Ultromics develops and sells the EchoGo platform, a cloud-based AI-powered SaaS solution that analyzes routine echocardiogram video clips to detect complex cardiac diseases including heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. The platform powers FDA-cleared medical devices (EchoGo Heart Failure, EchoGo Amyloidosis, and EchoGo Core) that deliver automated structured DICOM reports to PACS systems within 20 minutes, targeting hospitals and healthcare systems in the U.S. and U.K.

Product overview

Ultromics offers the EchoGo platform, a unified AI-powered SaaS solution for cardiovascular disease detection through echocardiography analysis. The platform comprises two FDA-cleared diagnostic modules: EchoGo Heart Failure for detecting heart failure with preserved ejection fraction (HFpEF), and EchoGo Amyloidosis for cardiac amyloidosis screening. Both modules leverage deep learning computer vision models trained on over 10 years of outcome data to analyze routine echocardiogram video clips and deliver automated diagnostic reports within 20 minutes. The platform integrates with existing hospital PACS infrastructure and is reimbursable under CPT code 0932T ($316 per analysis).

Differentiator

Problem solved

Functional benefit

Brands

  • EchoGo Heart Failure: FDA-cleared AI-powered diagnostic support tool for detecting heart failure with preserved ejection fraction (HFpEF) from routine echocardiogram analysis.
  • EchoGo Amyloidosis
  • EchoGo Core
  • EchoGo Platform

Products and services

  • EchoGo Platform

Quantifiable outcome

  • EchoGo Heart Failure achieves 90% sensitivity and 86% specificity for HFpEF detection
  • +5 more outcomes

Companies that use Ultromics

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Ultromics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature4 records

Ultromics partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core.

  • PfizercoreStrategic or Co-development Partner · 1 January 2024Co-development partner for EchoGo Amyloidosis device, contributing to FDA Breakthrough Device Designation and marketing authorization through TAP program.
  • Johnson & Johnson Innovative MedicinecoreStrategic or Co-development Partner · 1 January 2021Collaboration to develop EchoGo Amyloidosis AI platform using artificial intelligence to detect cardiac amyloidosis from routine echocardiograms. Platform received FDA Breakthrough Device Status and is prepared for U.S. commercialization.
  • Mayo CliniccoreStrategic or Co-development PartnerKey clinical validation partner; built EchoGo in collaboration with Mayo Clinic; hosts key opinion leaders including Dr. Patricia Pellikka; contributed to multiple clinical studies.
  • NHS UKcoreStrategic or Co-development PartnerTechnology built in partnership with NHS for echocardiography analysis; supported by NHS England; deployed across NHS sites.
  • FNIH (Foundation for the National Institutes of Health)coreStrategic or Co-development PartnerPartner in Accelerating Medicines Partnership Heart Failure (AMP HF) 5-year, $37 million multi-stakeholder collaboration to investigate HFpEF.
  • American Society of Echocardiography (ASE)coreStrategic or Co-development PartnerASE IRT partnership; member and leader of ASE AI taskforce setting principles and guidance for AI in echocardiography.
  • University of OxfordcoreStrategic or Co-development PartnerSpin-out company founded at Oxford University in 2017; ongoing research partnership with Oxford Cardiovascular Clinical Research Facility.
  • Cleveland CliniccoreTechnology or IntegrationClinical validation partner; conducted utility study of EchoGo for COVID-19 risk stratification.
  • MedStar HealthcoreTechnology or IntegrationWASE-COVID study partner; Director Dr. Federico Asch served as principal investigator.
  • Northwestern MedicinecoreTechnology or IntegrationEchoGo HFpEF clinical deployment partner; published initial experience study with Dr. Akhil Narang.
  • Microsoft AzurecoreTechnology or IntegrationCloud infrastructure provider for EchoGo platform; data centers in UK and North America.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Ultromics competitors and assessment

Company assessment

Emerging players

  • Cleerly: Cleerly applies AI to cardiac CT imaging for plaque and ischemia assessment; competes with Ultromics in AI-driven cardiovascular diagnostics but uses a different imaging modality and use case.
  • HeartFlow: HeartFlow provides AI-driven cardiac CT FFR analysis for coronary disease; a comparable AI-cardiology-diagnostics peer but focused on CT rather than echocardiography and ischemia rather than HFpEF/amyloidosis.
  • Eko Health: Eko Health builds AI-enabled cardiac ultrasound and digital stethoscope devices with embedded AI for cardiac disease detection; competes at the intersection of point-of-care ultrasound and AI diagnostics adjacent to Ultromics' echo AI.
  • RapidAI: RapidAI offers AI imaging analysis platforms initially focused on stroke and expanding into other vascular/cardiac conditions; comparable as an AI imaging diagnostics vendor to hospital systems.
  • Viz.ai: Viz.ai applies AI to medical imaging workflow across multiple specialties, including cardiology, and competes with Ultromics in AI-powered cardiac imaging analytics and hospital deployment.

Direct peers

  • Caption Health (GE HealthCare): Acquired by GE HealthCare in 2023, Caption Health was the leading AI-guided echocardiography acquisition and analysis platform and is the closest direct competitor to Ultromics' EchoGo platform, serving similar cardiology workflows.
  • Us2.ai: Us2.ai develops AI software that automates echocardiogram analysis for cardiac function assessment, directly competing with EchoGo Core and EchoGo Heart Failure on AI-driven cardiac measurement and disease detection.
  • DiA Imaging Analysis: DiA Imaging Analysis provides AI-based ultrasound image analysis tools, including cardiac applications, that compete with Ultromics' EchoGo Core automated measurement capabilities for echocardiography.

Broad incumbents

  • Tempus Labs: Tempus is a large AI-driven precision medicine company with capabilities spanning imaging, pathology, and clinical data; while not a focused echocardiography peer, it competes broadly for AI diagnostics budget and hospital AI partnerships.
  • Philips (Cardiology Informatics): Philips operates Intellispace Cardiovascular and cardiology informatics suites sold into the same hospital systems as Ultromics; multiple Ultromics executives came from Philips cardiology informatics, making it the most directly comparable incumbent competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Ultromics social profiles

Digital presence

Ultromics compliance and trust

Trust signal

Compliance5 records

Ultromics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ultromics leadership team

Management profile

Number of profiles

Profiles9 records

Ultromics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ultromics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ultromics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ultromics

What does Ultromics do?

Ultromics develops and sells the EchoGo platform, a cloud-based AI-powered SaaS solution that analyzes routine echocardiogram video clips to detect complex cardiac diseases including heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. The platform powers FDA-cleared medical devices (EchoGo Heart Failure, EchoGo Amyloidosis, and EchoGo Core) that deliver automated structured DICOM reports to PACS systems within 20 minutes, targeting hospitals and healthcare systems in the U.S. and U.K.

Is Ultromics a public or private company?

Ultromics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ultromics founded?

Ultromics was founded in 2017. It employs 51 to 100 people.

Where is Ultromics based?

Ultromics is headquartered in Oxford, United Kingdom, in the Europe region.

How does Ultromics make money?

Two revenue lines are on record. EchoGo Heart Failure Analysis are the primary driver. The others are saaS Platform Services.

Who are Ultromics's main competitors?

Emerging players on record are Cleerly, HeartFlow, Eko Health, RapidAI and Viz.ai. Direct peers are Caption Health (GE HealthCare), Us2.ai and DiA Imaging Analysis. Broad incumbents are Tempus Labs and Philips (Cardiology Informatics).

Does Ultromics have an API?

No public API is recorded for Ultromics.

What industry is Ultromics in?

Ultromics's product category is AI Cardiac Diagnostics Software. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAHABAI, Imaging Informatics & Workflow (PACS/RIS/VNA). Its NAICS code is 621511 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magReport: Ultromics’ AI Algorithm May Identify HFpEF Earlier Than Standard CareUltromics reported that its EchoGo Heart Failure AI algorithm could identify heart failure with preserved ejection fraction up to 263 days earlier than standard care. Modeled results for 10,000 patients over five years suggest 477 lives saved, 406 fewer hospital admissions, and $1.9 million in additional revenue. The evaluation was conducted by the American Heart Association's AI Assessment Lab.GlobeNewswireAI Disruption in Cardiovascular Devices Accelerates as Investment Surpasses $300 Million and FDA-Cleared Algorithms Top 120BCC Research released its AI Impact on Cardiovascular Devices Market report, citing over 120 FDA-cleared AI algorithms in cardiology as of 2024 and investment rounds totaling more than $300 million, including Cleerly's $106 million Series C, Ultromics' $55 million Series C and Octagos Health's $43 million Series B. The report also notes government funding, wearable ECG accuracy of 88% and 99% negative predictive value, and regulatory fragmentation risks.YahooNew AHA report highlights Ultromics’ AI tool’s benefit in earlier heart failure diagnosisA new American Heart Association Impact Report, based on independent clinical and image data from its AI Assessment Lab, found that Ultromics' EchoGo Heart Failure AI algorithm can identify patients with heart failure with preserved ejection fraction (HFpEF) an average of 263 days earlier than standard clinical care. The report projects that early intervention using the tool could save 477 lives per 10,000 patients over five years and generate cost-savings of up to $1.9 million for health systems. HFpEF is notoriously difficult to diagnose due to non-specific symptoms and diagnostic bias against women and ethnic minorities, making earlier detection critical for improving patient outcomes.Medical Device NetworkNew AHA report highlights Ultromics’ AI tool’s benefit in earlier heart failure diagnosisThe American Heart Association published an Impact Report finding that Ultromics' EchoGo Heart Failure AI algorithm could identify patients with heart failure with preserved ejection fraction (HFpEF) an average of 263 days earlier than standard clinical care. The independent validation conducted through AHA's AI Assessment Lab also projects that early intervention could save 477 lives per 10,000 patients over five years and generate cost savings of up to $1.9 million for health systems. The Oxford, UK-headquartered company developed the AI tool to automate echocardiogram analysis and standardize diagnoses, addressing a recognized diagnostic bias where HFpEF is often underdiagnosed in women and ethnic minorities.PR NewswireAmerican Heart Association AI Assessment Lab Report Finds Ultromics' EchoGo® Heart Failure May Identify HFpEF Earlier Than Standard CareThe American Heart Association AI Assessment Lab evaluated Ultromics' EchoGo Heart Failure algorithm, finding it could identify heart failure with preserved ejection fraction up to 263 days earlier than standard care. The analysis projects 477 lives saved per 10,000 patients over five years and up to $1.9 million in additional revenue for health systems.TheimagingwireVC Funding Bounces Back in 2025Venture capital funding for medical imaging AI companies rebounded significantly in 2025, with total funding more than doubling to $709 million from $336 million the prior year, according to Signify Research. While the number of funding rounds fell 17% to 19, the average funding round size grew 112% to $39 million, reflecting increased investor selectivity toward companies with clear enterprise fit and platform integration capabilities. Notable 2025 funding rounds included Aidoc's $150 million raise, Ultromics joining the $100 million club, Cerebriu's $10 million Series A, and a2z's $4.5 million seed round.Business WeeklyBiotech investors want to see a clear strategyBiotech investors are increasingly prioritizing clear strategic plans, robust governance, and well-managed intellectual property, reflecting a shift toward more selective funding decisions with capital concentrated in better-prepared companies. The Oxford-Cambridge Growth Corridor has emerged as the UK's leading investment region, with early-stage life sciences and deep-tech companies securing £7.9 billion since 2015, including recent raises by CellCentric ($120m Series C), Constructive Bio ($58m Series A), NRG Therapeutics (£50m Series B), and Ultromics ($55m Series C). UK life sciences investment in early 2025 reached its strongest first-quarter level since 2021, supported by the government's £13 billion infrastructure commitment to the corridor.Mpo-magAmerican Heart Association Ventures Invests in UltromicsUltromics Ltd. has secured an investment from the American Heart Association's Go Red for Women Venture Fund to accelerate expansion of its FDA-cleared AI technology for detecting heart failure with preserved ejection fraction (HFpEF), a condition that disproportionately affects women and often goes undiagnosed. The company's EchoGo Heart Failure system analyzes routine ultrasound scans and achieves diagnostic decisions in 93% of patients compared to current clinical risk scores that are non-diagnostic in 60% of cases, having already processed over 430,000 echocardiograms across U.S. and U.K. hospitals. The investment reflects a shared commitment to closing the diagnostic gap for HFpEF, which is a leading cause of death for women.MedCity NewsAHA Invests in AI that Tackles Cardiology’s Gender Bias ProblemThe American Heart Association invested in the British AI startup Ultromics through its Go Red for Women Venture Fund to address longstanding gender disparities in heart disease diagnosis and treatment. Ultromics has developed an AI platform that analyzes echocardiograms to detect hard-to-diagnose conditions like heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis, which disproportionately affect women and often go undiagnosed due to subtle or non-classic presentations. The company will use the capital to scale adoption of its platform across U.S. hospitals, building on its existing use at health systems including Northwestern Medicine, University Hospitals, and University of Chicago Medicine.Rappahannock NewsUltromics Secures Strategic Investment from the American Heart Associa...Ultromics, an Oxford-based AI cardiology company, announced a strategic investment from the American Heart Association's Go Red for Women Venture Fund, the fund's second investment, to accelerate its FDA-cleared EchoGo Heart Failure platform for detecting heart failure with preserved ejection fraction (HFpEF). The AI platform has analyzed over 430,000 echocardiograms and achieves diagnostic decisions in 93% of patients, compared to a 60% non-diagnostic rate with current clinical risk scores. The investment targets a significant health equity gap, as women are twice as likely to develop HFpEF and up to 64% of cases go undiagnosed in clinical practice.